CI insider files Form 144 to sell 35,711 Cigna shares on NYSE
Rhea-AI Filing Summary
Cigna Group (CI) submitted a Form 144 proposing the sale of 35,711 shares of its common stock, with an aggregate market value of $9,822,667.66, to be executed on 08/12/2025 through Fidelity Brokerage Services LLC on the NYSE. The filing lists total shares outstanding of 266,928,075 and shows the securities to be sold were acquired through option exercises and restricted stock vesting between 02/26/2021 and 08/12/2025, with some purchases paid in cash and others issued as compensation.
The filer reports no securities sold by the same person in the past three months and includes the standard attestation that the seller has no undisclosed material information; the notice is marked LIVE.
Positive
- None.
Negative
- None.
Insights
Planned insider sale of 35,711 shares valued at $9.82M; holdings largely from options and vesting.
The Form 144 documents a proposed sale executed through Fidelity on 08/12/2025 of 35,711 common shares with an aggregate value of $9,822,667.66. Acquisition details show multiple option grants (02/24/2021 and 02/23/2022), restricted stock vesting events from 2021 through 2025, and a stock option exercise on 05/15/2024. No sales by the same person are reported in the prior three months. This is a routine regulatory notice required before an insider sale.
Routine Form 144 filing with attestation of no undisclosed material information and no recent sales reported.
The filing includes the customary signature representation that the seller does not possess material nonpublic information and references Rule 10b5-1 trading plans if applicable. The schedule details the provenance of the shares being sold (options, vesting, cash-paid exercises) and confirms the transaction will occur on the NYSE via Fidelity. From a governance perspective, the document fulfills disclosure obligations for an insider disposition.